Lampalizumab

Lampalizumab
Monoclonal antibody
Type	Fab fragment
Source	Humanized (from mouse)
Target	CFD
Clinical data
Routes of; administration	Intravitreal
ATC code	none;
Identifiers
CAS Number	1278466-20-8;
IUPHAR/BPS	8294;
ChemSpider	none;
UNII	UWU93Y99R3;
KEGG	D10440;
Chemical and physical data
Formula	C2068H3214N546O676S13
Molar mass	46958.39 g·mol−1

Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody that binds to complement factor D; it was developed as a potential treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration.^[1]^[2]

One of the two Phase 3 clinical trials (Spectri) was interrupted on September 8, 2017 due to failure to meet primary end point.^[3] The second Phase 3 clinical trial (Chroma) also failed to meet its primary end point.^[4]

These two failures have called into question whether complement inhibition is a sound strategy for geographic atrophy.^[5]

References

^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
^ "Statement On A Nonproprietary Name Adopted By The USAN Council - Lampalizumab" (PDF). American Medical Association.
^ "Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration". www.roche.com. Retrieved 2017-09-14.
^ "Statement on Chroma Study". www.roche.com. Retrieved 2017-11-10.
^ Dolgin E (November 2017). "Age-related macular degeneration foils drugmakers". Nature Biotechnology. 35 (11): 1000–1001. doi:10.1038/nbt1117-1000. PMID 29121027. S2CID 9682962.

This monoclonal antibody–related article is a stub. You can help Justapedia by expanding it.

[1] World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).

[2] "Statement On A Nonproprietary Name Adopted By The USAN Council - Lampalizumab" (PDF). American Medical Association.

[3] "Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration". www.roche.com. Retrieved 2017-09-14.

[4] "Statement on Chroma Study". www.roche.com. Retrieved 2017-11-10.

[5] Dolgin E (November 2017). "Age-related macular degeneration foils drugmakers". Nature Biotechnology. 35 (11): 1000–1001. doi:10.1038/nbt1117-1000. PMID 29121027. S2CID 9682962.

[1]

[2]

[3]

[4]

[5]

Lampalizumab

References

Navigation menu